To explore the effect of transcranial stimulation on the therapeutic effect and immune function of patients with post-stroke depression (PSD). Methods Selection in September 2020–April 2021 on the diagnosis of 70 patients with PSD as the research object, 35 patients were randomly divided into control group and intervention group and control group given conventional treatment, the intervention group in the control group on the basis of the application of transcranial magnetic stimulation treatment, compare the curative effect of two groups of patients after the treatment cycle and the effects on the immune function. Results After treatment, the levels of DA, NE, 5-HT in 2 groups were significantly increased, and those in the observation group were significantly higher than those in the control group (P < 0.05). After 8 weeks of treatment, serum Gly content in 2 groups was significantly increased and Glu content was significantly decreased compared with before treatment. Compared with the control group, serum Gly content in observation group was significantly increased and Glu content was significantly decreased after treatment (P < 0.05). After 8 weeks of treatment, the contents of IL-1β, IL-6 and TNF-α in serum of 2 groups were significantly decreased, compared with the control group, the contents of IL-1β, IL-6 and TNF-α in serum of observation group were significantly decreased (P < 0.05); Before treatment, there was no significant difference in PHQ-9 score and MBI score between the two groups (P > 0.05). After 8 weeks of treatment, PHQ-9 score and MBI score in the two groups were better than before treatment, and the observation group was better than the control group (P < 0.05). Conclusion Transcranial magnetic stimulation therapy can not only effectively promote the synthesis and release of monoamine neurotransmitters in patients with post-stroke depression, regulate the inhibitory/excitatory amino acid neurotransmitters, reduce inflammatory response, improve the clinical treatment effect and enhance the immune function of PSD patients, which has clinical application value.

探讨经颅刺激对脑卒中后抑郁症（PSD）患者疗效及免疫功能的影响。方法选择2020年9月-2021年4月诊断为PSD的70例患者作为研究对象，35例患者随机分为对照组和干预组，对照组给予常规治疗，干预组在对照组的基础上应用经颅磁刺激治疗，比较两组患者治疗周期后的疗效及对免疫功能的影响。结果治疗后2组DA、NE、5-HT水平均明显升高，观察组明显高于对照组（P < 0.05）。经过8周的治疗，与治疗前相比，2组血清Gly含量明显升高，Glu含量明显降低。与对照组比较，观察组治疗后血清Gly含量显着升高，Glu含量显着降低（P < 0.05）。治疗8周后，2组血清中IL-1β、IL-6、TNF-α的含量显着降低，与对照组相比，IL-1β、IL-6、TNF-α的含量明显低于对照组。观察组血清显着降低（P < 0.05）；治疗前，两组PHQ-9评分、MBI评分比较差异无统计学意义（P>0.05）。治疗8周后，两组PHQ-9评分、MBI评分均优于治疗前，观察组优于对照组（P < 0.05）。结论 经颅磁刺激治疗不仅能有效促进脑卒中后抑郁患者单胺类神经递质的合成和释放，调节抑制性/兴奋性氨基酸类神经递质，降低炎症反应，提高临床治疗效果，增强PSD的免疫功能。患者，具有临床应用价值。